Cas:80454-42-8 Paeoniflorigenone manufacturer & supplier

Chemical Name:Paeoniflorigenone

CAS.NO:80454-42-8

Synonyms:[(1S,3R,6S,8S,10S)-8-Hydroxy-3-methyl-5-oxo-2,9-dioxatricyclo[4.3.1.0]dec-10-yl]methyl benzoate;2,5-Methano-1,3-benzodioxol-6(5H)-one, 8-[(benzoyloxy)methyl]tetrahydro-3a-hydroxy-7a-methyl-, (2S,3aS,5S,7aR,8S)-

Molecular Formula:C₁₇H₁₈O₆

Molecular Weight:318.321

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:481.1±45.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.605

PSA:82.06000

Exact Mass:318.110352

LogP:2.87

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [(1S,3R,6S,8S,10S)-8-Hydroxy-3-methyl-5-oxo-2,9-dioxatricyclo[4.3.1.0]dec-10-yl]methyl benzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,5-Methano-1,3-benzodioxol-6(5H)-one, 8-[(benzoyloxy)methyl]tetrahydro-3a-hydroxy-7a-methyl-, (2S,3aS,5S,7aR,8S)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[(1S,3R,6S,8S,10S)-8-Hydroxy-3-methyl-5-oxo-2,9-dioxatricyclo[4.3.1.0]dec-10-yl]methyl benzoate Use and application,2,5-Methano-1,3-benzodioxol-6(5H)-one, 8-[(benzoyloxy)methyl]tetrahydro-3a-hydroxy-7a-methyl-, (2S,3aS,5S,7aR,8S)- technical grade,usp/ep/jp grade.

Related News: but are not expected to recover the costs of developing and marketing a treatment drug.” Due to the high costs and low demands of the drug product, it is important to efficiently use API supply during the formulation process. 2,3-dihydro-1,4-dihydroxyanthraquinone manufacturers Immunocompromised people account for roughly 2.7% of U.S. adults including patients who’ve received an organ transplant, living with HIV or have received active or recent treatment for cancer, Oliver said. spiro[4.4]nonane-1,4-dione suppliers For its part, the FDA’s representative at the meeting, Doran Fink, M.D., said the drug regulator is “working as rapidly as possible to conduct a thorough and comprehensive” review of all the COVID-19 vaccines that have applied for full approval. Pfizer and Moderna recently submitted their applications for a full nod. morpholine-4-carboxylic acid 3,4-dithia-hexane-1,6-diyl ester vendor & factory Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly.,but are not expected to recover the costs of developing and marketing a treatment drug.” Due to the high costs and low demands of the drug product, it is important to efficiently use API supply during the formulation process.